In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

Robyn Kalda
3 days ago
1 min read

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy patients. Using rats, the researchers determined that PRDX2 helped reduce inflammation, suggesting that it has a protective role and might have therapeutic use.

Read the Scientific Reports article

Recent Posts

Early diagnosis and treatment of PAH improve survival

This study examined the causes of delayed diagnosis (diagnosis after approximately 22 months) of pulmonary arterial hypertension (PAH) and whether an earlier diagnosis (within six months) leads to bet

Blood test identified as a good biomarker for idiopathic PAH

A relatively simple, inexpensive, and minimally invasive test for idiopathic pulmonary arterial hypertension (IPAH) would aid in the diagnosis of this disease. This study found that levels of the NOTC

Doctors and patients recognize PAH symptom severity differently

As pulmonary arterial hypertension (PAH) patients became sicker, their self-reported quality of life was significantly worse than their doctors recognized. This discordance was associated both with wo

Comments